1. Drug development approaches for poorly soluble compounds
2. Solid dispersion technique to improve solubility and, thereby, bioavailability
3. Nanosizing of drugs to improve the apparent dissolution and bioavailability
4. Pharmaceutical Co-crystals
5. Self-micro emulsifying and self-emulsifying drug delivery systems to improve solubility and bioavailability
6. Liposomes and mixed micelles for improvement of drug solubility
7. Improvement of solubility and bioavailability of poorly soluble drugs using mesoporous silica particles
8. Gastrointestinal Dissolution and Absorption of BCS Class II Drugs
9. Cyclodextrin-Based Formulations to Improve Solubility of poorly soluble drugs
10. Cosolvent-based formulations to improve solubility and bioavailability
11. First in-animal studies and formulation considerations
12. Improving aqueous solubility of drug candidates through structural modifications
1. Drug development approaches for poorly soluble compounds
2. Solid dispersion technique to improve solubility and, thereby, bioavailability
3. Nanosizing of drugs to improve the apparent dissolution and bioavailability
4. Pharmaceutical Co-crystals
5. Self-micro emulsifying and self-emulsifying drug delivery systems to improve solubility and bioavailability
6. Liposomes and mixed micelles for improvement of drug solubility
7. Improvement of solubility and bioavailability of poorly soluble drugs using mesoporous silica particles
8. Gastrointestinal Dissolution and Absorption of BCS Class II Drugs
9. Cyclodextrin-Based Formulations to Improve Solubility of poorly soluble drugs
10. Cosolvent-based formulations to improve solubility and bioavailability
11. First in-animal studies and formulation considerations
12. Improving aqueous solubility of drug candidates through structural modifications

Yogeshwar Bachhav is a pharmacist by training and holds a PhD in drug delivery systems from ICT, Mumbai (India). He has worked as research scientist for several years on a collaborative project between Pantec Biosolutions and Geneva University (Switzerland), and as formulation manager at Debiopharm Group, Lausanne (Switzerland). For the last several years he has been associated with AiCuris Anti-infective Cures AG (Germany) as in-charge for Pharmaceutical development of new drugs. In total, he has around 16 years of experience in the preformulation and formulation development of small molecules and peptides for oral, dermal and parenteral application and in drug substance manufacturing.